ARCHIVES

Risk-Benefit Analysis Advised Prior To Hormone Therapy

This article is from The Cancer Letter archive.

Vol. 33 No. 8 | August 27, 2010

Download PDF Visit The Full Archive

Related Articles

At AAAS Meeting, David Baltimore Comments on Bush Administration Science Policy.

March 3, 2006

MGI Pharma, MethylGene Begin Phase II Trial Of MG98.

September 28, 2001

AACR, Kellogg’s Co. Sponsor Award

January 5, 1996

Danish Researchers Post Long-Awaited Aranesp Results–Ever So Discreetly.

February 16, 2007

Senate Approves Supplemental Funds For NIH and FDA.

May 23, 2008

Congresswoman Urges Increased Funding For Cancer information Service

August 11, 1989